65,437 trials
Healthy Volunteers · Anti-Bacterial Agents · Methicillin-Resistant Staphylococcus Aureus
Primary: Evaluation of the Safety of N-Rephasin® SAL200 in Healthy Human Volunteers — 1; 0; 2; 1 Participants
Alzheimer Disease
Primary: Total Source Organ Counts Based on Individualized Organ Volumes of Interest (VOIs) — 0.33530; 0.59398; 2.13730; 4.89330 Percentage of Injected Dose
Allergic Rhinitis · Asthma · Latent Tuberculosis
Primary: IFN-y Protein Response in Mucosal Lining Fluid — NA; 3.29; 9.42; 8.20 pg/hr/ml
Cleft Lip · Scarring · Cleft Palate
Primary: Hypertrophic Scarring (HTS) as Assessed by Score on the Manchester Scar Scale (MSS) Rated by Blinded Plastic Surgeons — 7; 9 score on a scale
Posttraumatic Stress Disorder
Primary: Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) — 93.3 score on a scale
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Complete Pathological Response (pCR) of PET/CT Non-responders — 17.95; 20 percentage of participants with a pCR — p=1.0
Type 2 Diabetes
Primary: Glycemic Control at Hospital Discharge and 6 Months Follow up — 8.3; 8.4; 7.13; 7.68 % (mmol/mol)
Anesthesia
Primary: Number of Participants With Leakage Observed During Procedure — 0 Participants
B-cell Lymphoid Malignancies
Primary: Part 1 : Number Of Participants Experiencing Adverse Events — 12; 7 Participants
Anatomic Total Shoulder Arthroplasty
Primary: Difference in Glenoid Component Placement (Inclination and Version) — 4.1; 3.1; 4.3; 4.0 degree
Non-Alcoholic Fatty Liver Disease · Hepatitis B · Vaccine Reaction
Primary: Anti-HBs Titres (IU/L) — 642; 385 Anti-HBS IU/L — p=0.02
Community-acquired Pneumonia
Primary: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC) From Time 0 to 48 Hours After Dosing (AUC[0-48]) of Oral Omadacycline on Day 2 — 9.93 Hours x…
End Stage Liver Disease
Primary: Number of Eligible Participants Enrolled in the Study — 50 Participants
Lung Transplant Rejection · Antibody-mediated Rejection
Primary: Donor-specific HLA Antibodies, Re-transplantation, or Death — 0; 5; 3; 3 participants
Multiple Sclerosis
Primary: Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period — 0.54; 0.67 Confirmed relapses — p=0.0024